Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
BACKGROUND Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS Adult refractory ITP patients (<30,000 platelets/µL) were enrolled. Eltrombopag doses were increased to achieve a target platelet count (≥5...
متن کاملEltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Chronic immune thrombocytopenia (ITP) is an auto-immune disease characterized by immune-mediated platelet destruction and reduced platelet production caused by antiplatelet autoantibodies, leading to a marked decrease in platelet count and rarely life-threat...
متن کاملSevere Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune globulin, rituximab, cyclosporine, azathioprine, vincristine, mycophenolate mofetil, romiplostim, and eltrombopag; however, it achieved complet...
متن کاملSafety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Patients with chronic immune thrombocytopenia may have bleeding resulting from low platelet counts. Eltrombopag increases and maintains hemostatic platelet counts; however, to date, outcome has been reported only for treatment lasting ≤ 6 months. This interim analysis of the ongoing open-label EXTEND (Eltrombopag eXTENded Dosing) study evaluates the safety and efficacy of eltrombopag in 299 pat...
متن کاملRomiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
OBJECTIVES Immune thrombocytopenia (ITP) causes increased platelet destruction and suboptimal platelet production, increasing risk of bleeding. This analysis uses a Bayesian metaregression model to indirectly compare effectiveness of the thrombopoietin mimetics romiplostim and eltrombopag for increasing platelet counts, and contrasts the results with those of non-Bayesian approaches. METHODS ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Research
سال: 2015
ISSN: 2287-979X,2288-0011
DOI: 10.5045/br.2015.50.1.19